arrow
M

Martin Filipits

Medical University of Vienna
H指数:57
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

High-grade serous ovarian cancer is associated with increased TP53 mutation burden in uterine lavage

高级别浆液性卵巢癌与子宫灌洗液中TP53突变负荷增加相关

2026-08-290
OA
Absence of EGFR signalling in granulocytic cells relieves immunosuppression sensitising CRC metastases to immune checkpoint therapy

粒系细胞中EGFR信号缺失缓解免疫抑制,使结直肠癌转移灶对免疫检查点疗法更敏感

2026-08-110
OA
The Xpert Breast Cancer Insight Test Predicts Distant Recurrence and Overall Survival in ER-Positive, HER2-Negative Early Breast Cancer

Xpert乳腺癌洞察测试可预测ER阳性、HER2阴性早期乳腺癌的远处复发和总生存期

2026-07-010
OAAI
ESR1, PGR, ERBB2, and MKi67 mRNA expression in diagnostic core biopsies from breast cancer patients of the ABCSG Trial 34

ABCSG试验34中乳腺癌患者诊断性核心活检样本中的ESR1、PGR、ERBB2和MKi67 mRNA表达

2025-10-300
OAAI
Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trials
BREAST
IF7.9
2025-04-010
OAAI
HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXd

HER2和HER3在HER2阴性早期乳腺癌新辅助治疗期间的表达:T-DXd和HER3-DXd生物标志物驱动的序贯治疗的潜力

2025-01-060
PRE
Monocyte subsets in breast cancer patients under treatment with aromatase inhibitor and mucin-1 cancer vaccine
2024-10-080
OAAI
Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting? (Jan, 10.1007/s10549-023-07186-6, 2024)
2024-05-050
OAAI
Pathological response according to early metabolic remission in an interim FDG-PET scan and to tumor infiltrating lymphocytes - A secondary analysis of the phase II trial ABCSG 52/ATHENE investigating atezolizumab in early HER2+BC
2024-05-020
PRE
Protocol-defined biomarker analysis in the PALLAS (AFT-05) adjuvant trial: Genomic subtype derived from RNA sequencing of HR+/HER2-early breast cancer
2024-05-020
PRE
Immunohistochemical markers and determinants of clinical response in the Penelope-B trial
2023-03-010
PRE
Development and Validation of a Composite Biomarker Predictive of Palbociclib plus Endocrine Treatment Benefit in Early Breast Cancer: PENELOPE-B and PALLAS Trials
2023-03-011
PRE
Outcome analysis of HER2-zero or HER2-low hormone receptor-positive (HR plus ) breast cancer patients - characterization of the molecular phenotype in combination with molecular subtyping
2023-03-012
PRE